INSULIN ASPART IN A 30 70-PREMIXED FORMULATION - PHARMACODYNAMIC PROPERTIES OF A RAPID-ACTING INSULIN ANALOG IN STABLE MIXTURE/

OBJECTIVE - To study the pharmacodynamic properties of a 30/70 premixe d formulation of the rapid-acting insulin analog insulin aspart (B28As p) and its protamine-retarded preparation (30/70 IA) in comparison wit h a respective mixture of soluble human insulin and NPH insulin (30/70 HI). RESEARCH DESIGN AND METHODS - In this single-center double-blind euglycemic glucose-clamp study 24 healthy male volunteers (age, 26 +/ - 2 years; BMI, 23.7 +/- 1.7 kg/m(2)) received single subcutaneous inj ections of 0.3 U/kg body wt of either 30/70 IA or 30/70 HI on 2 study days in randomized order. Glucose infusion rates (GIRs) were determine d over a 24-h period after administration. RESULTS - The injection of 30/70 IA resulted in an earlier onset and more pronounced peak of acti on (t(max), 127 +/- 24 min; GIR(max), 9.7 +/- 2.3 mg . kg(-1) . min(-1 )) than 30/70 HI (t(max), 185 +/- 52 min; GIR(max) 7.4 +/- 1.7 mg . kg (-1) . min(-1)) (P < 0.001). The metabolic activity of 30/70 IA (measu red as the sum of the glucose infused) within the first 4 h after inje ction was 37% greater than that of 30/70 HI (P < 0.0001), while the to tal metabolic potencies over 24 h of both preparations were comparable . CONCLUSIONS - The 30/70 premixed formulation of insulin aspart shows a significantly greater metabolic effect in the first 4 h after subcu taneous injection than the 30/70 mixture of human insulin. Insulin asp art retains its pharmacodynamic properties in a premixed 30/70 formula tion.